I lost over 5 stone and stopped taking Mounjaro for good… here's how I made sure I didn't pile all the weight back on
WEIGH TO GO! I lost over 5 stone and stopped taking Mounjaro for good… here's how I made sure I didn't pile all the weight back on
Click to share on X/Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
A WOMAN has shared what happened to her once she stopped taking fats jabs.
As a growing number of people proudly share their jaw-dropping Mounjaro transformations, one woman, Anne Neni has revealed what's happened to her ever since she dropped the popular jab from her routine.
3
Anne Neni took to TikTok to reveal how she didn't gain all the weight back after coming off Mounjaro
Credit: TIKTOK/@neni_anne
3
The young woman, from the UK, not only maintained the new weight - but even managed to shed some more
Credit: TIKTOK/@neni_anne
While some have reported putting all the lost weight back on, Anne recently claimed that hasn't been the case for her - and what's more, she's even managed to drop some extra.
The young woman, from the UK, told TikTok users that she jumped on the trend to shed over 5 stone - which she eventually did.
''When I got to my goal weight, I decided to go off Mounjaro gradually,'' Anne shared in a video.
''So, from the 10mg I went down to 5mg, and then to 2.5mg,'' she said, adding that she stayed on the final dose for three weeks.
''At the time, I felt like I was okay and I didn't need to take Mounjaro anymore.''
After being Mounjaro-free for two weeks, Anne discovered that she hadn't piled the weight back - which is the main fear for many on the fat jab.
''As a matter of fact, I have lost 0.5kg (1.1lbs) - and that's because I was so sceptical about what to eat while I am off Mounjaro.
''I am very careful, continuing with the habits that I learnt on MJ [Mounjaro], continuing my intermittent fasting.''
Put simply, intermittent fasting is an eating plan where people switch between fasting and eating on a regular schedule, typically sticking to the 16:8 eating window (16 hours of no food and 8 hours of meals).
Numerous celebs and influencers swear by this method, with Hugh Jackman reportedly trying it to beef up for X-men movies.
I lost 8st on Mounjaro - hubby doesn't mind my loose skin, now we can try for kids
Research suggests that intermittent fasting, also loved by Jennifer Aniston, could help with weight loss and managing conditions like cholesterol.
However, it's worth noting that this diet is not suitable for everyone.
As well as following the 16:8 intermittent fasting method, Anne keeps her protein intake high to ensure she feels satiated after every meal.
''I hydrate when I need and I have been so, so conscious of my meals.''
She told her 17.2k followers on the platform: ''So, if you are thinking of coming off Mounjaro, utilise every opportunity you have on Mounjaro.
''Embrace the hunger and learn the strategies on how to manage your body because let me tell you - there is hunger on the other side.''
The risks of taking Mounjaro
Mounjaro is regarded by some as the King Kong of weight loss jabs.
Sun GP Dr Zoe Williams acknowledged that Mounjaro, which could soon be rolled out on the NHS, can save the lives of people with 'life-threatening levels of obesity.'
But despite this, the NHS warned: 'Never take an anti-obesity medicine if it has not been prescribed to you.
"These types of medicines may not be safe for you and can cause serious side effects.'
About half a million Brits use weight loss drugs - and the number is expected to double in the next year.
Mounjaro works by suppressing your appetite, making people feel fuller for longer.
3
The injections are licensed for patients with type 2 diabetes and to assist those who are clinically obese (with a Body Mass Index of 30 or over).
One jab is administered each week but the duration is dependent on someone's weight.
The drugs can be lawfully supplied when prescribed by a practitioner - such as a doctor, nurse or a pharmacist-independent prescriber.
But increasingly, people have been buying them through online pharmacies with insufficient checks.
Only recently, figures from the Medicines and Healthcare products Regulatory Agency revealed fat jabs had been linked to 82 deaths across the UK.
And the family of a man from Burton upon Trent, Staffs, who died after taking Mounjaro, are now calling for a probe into the jab's "potential to kill."
What to do if you lose too much weight too quickly whilst on Mounjaro
IF you're losing too much weight too quickly while on Mounjaro, it's important to take action to avoid potential health risks like muscle loss, malnutrition, dehydration, and fatigue. Here's what you can do:
Evaluate Your Caloric Intake
Mounjaro reduces appetite, which can make it easy to eat too little. If you're losing weight too fast (more than two to three lbs per week after the initial adjustment period), try: Tracking your food intake to ensure you're eating enough calories (apps like MyFitnessPal can help).
Increasing protein intake to preserve muscle mass (aim for 0.6–1g per pound of body weight).
Adding healthy fats and complex carbs (e.g., avocados, nuts, whole grains) for balanced energy.
Adjust Your Dosage (With Doctor's Approval)
If your weight loss is too rapid or causing side effects, your doctor may: Pause dose increases or lower your dosage.
Adjust your treatment plan to stabilise your weight loss.
Strength Training & Exercise
To prevent muscle loss: Incorporate resistance training at least two to three times per week.
Stay active with low-impact exercises like walking or yoga.
Hydrate & Manage Electrolytes Drink enough water (Mounjaro can reduce thirst).
Electrolytes matter - Consider adding magnesium, sodium, and potassium if you feel weak or fatigued.
Monitor for Malnutrition & Deficiencies
Rapid weight loss can cause vitamin/mineral deficiencies (especially B12, iron, and electrolytes). If you experience: Fatigue, hair loss, or dizziness, ask your doctor about supplements.
Consider Further Medical Guidance
If your weight loss is excessive or causing health concerns, speak with your healthcare provider.
They might adjust your dosage, diet, or exercise plan to help stabilise your weight loss.
'People aren't tracking what they eat while on Mounjaro'
The TikTok clip, which was posted under the username @neni_anne, has clearly left many open-mouthed, as it has quickly racked up over 252 views since being uploaded.
It's also amassed more than 5,000 likes, 228 comments and 569 shares at the time of writing.
Social media users were quick to flock to comments to share their thoughts - with fellow Mounjaro users also opening up about their experience with the jab.
One said: ''Even when you stop exercising, you will get all the weight back, even dieting.''
Someone else chimed in: ''I stopped 3 weeks ago and haven't gained a pound, still eating sensibly.''
''I took it from June till September, lost 2 stone 9lb and so far I haven't gained it back. Still not got a big appetite which is bizarre but I'm not complaining,'' a viewer commented.
''This is exactly it, my fear for a lot of people is they aren't tracking what they eat while on MJ, that's a recipe for disaster for lots of them,'' another thought.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Glasgow Times
an hour ago
- Glasgow Times
Mounjaro could help obese people control asthma says study
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. As an estimated 1.5 million people in the UK are now using weight loss drugs. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. Recommended reading: 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.' Who is eligible for Mounjaro on the NHS? At the moment, the rules are very strict, and treatment is being rolled out gradually by NHS England. NICE has recommended tirzepatide (Mounjaro) for weight management for eligible adults living with obesity, who also present with other weight-related health problems, including: dyslipidaemia (abnormal fat levels in the blood) hypertension (high blood pressure) obstructive sleep apnoea (when your breathing stops and starts while you sleep) cardiovascular disease (heart and blood vessel disease) type 2 diabetes mellitus Speak to your doctor for more information.
STV News
3 hours ago
- STV News
Weight-loss jabs could help obese people control asthma, study suggests
Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Professor Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
South Wales Guardian
5 hours ago
- South Wales Guardian
Weight-loss jabs could help obese people control asthma, study suggests
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'
